Clinical Trials in New York

Showing 8961-8980 of 19,464 trials

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

NCT02336165

This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts. Primary study objectives, which vary by cohort due to differences in subject populations, include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at 12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3), and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives include evaluation of the neurologic function and correlative biomarkers.

Glioblastoma

Ludwig Institute for Cancer Research159 participantsStarted Feb 2015

Los Angeles, California, United States • San Francisco, California, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 1< 1 mile

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

NCT00070070

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the immune system and stop tumor cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving vaccine therapy together with BCG and sargramostim in treating patients who have undergone cystectomy for transitional cell carcinomas.

Transitional Cell Carcinoma

Ludwig Institute for Cancer Research6 participantsStarted Oct 2003

New York, New York, United States

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Find Trials by Condition in New York

Effect of Training on Brain Volume in Ataxia

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

Study To Assess The Safety And Efficacy Of The Tempsure Flexsure Applicators For Abdominal Wrinkles

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Open-Label Safety Study of AXS-05 in Subjects With Depression

Expanded Access to Convalescent Plasma for Treatment of COVID-19

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Clot Dissolving Treatment for Blood Clots in the Lungs

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)